Form 4: uniQure CEO Matthew Kapusta Acquires Shares Through Performance-Based Units, Sells Portion for Tax Obligations

uniQure CEO Matthew Kapusta acquired 10,494 ordinary shares through vested performance-based restricted share units and sold 3,418 shares to cover tax obligations.

Summary

• Matthew Kapusta, CEO of uniQure N.V., acquired 10,494 ordinary shares on December 8, 2024, through the vesting of performance-based restricted share units (PRSUs).
• These PRSUs were granted on December 8, 2021, and vested due to the satisfaction of certain performance criteria.
• Each PRSU represents the right to receive one ordinary share.
• On December 9, 2024, Mr. Kapusta sold 3,418 ordinary shares at a price of $7.63 per share.
• The sale was executed to cover estimated withholding taxes associated with the vesting of the PRSUs.
• The sale was not a discretionary trade by Mr. Kapusta, but rather an automatic sale as part of the Performance Share Unit Agreement.
• Following these transactions, Mr. Kapusta beneficially owns 597,915 ordinary shares.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to executive compensation. The vesting of shares is positive, while the sale for tax purposes is neutral. Overall, the sentiment is slightly positive due to the performance-based vesting.

Positives

• The vesting of performance-based restricted share units indicates that performance criteria were met, which is a positive sign for the company.
• The acquisition of 10,494 shares by the CEO increases his stake in the company.

Negatives

• The sale of 3,418 shares, even for tax purposes, could be perceived negatively by some investors, although it was not a discretionary trade.

Risks

• The sale of shares by an executive, even for tax purposes, could potentially create short-term volatility in the stock price.
• The reliance on performance-based share units could create pressure on management to focus on short-term results.

Management Comments

• The sale of shares was not a discretionary trade by the Reporting Person, but rather an automatic sale as part of the Performance Share Unit Agreement.

Industry Context

This type of transaction is common for executives who receive equity-based compensation. The vesting of performance-based units and subsequent sale to cover taxes is a standard practice in the industry.

Comparison to Industry Standards

• Many biotech and pharmaceutical companies use performance-based restricted share units as part of their executive compensation packages, similar to uniQure.
• Companies like BioMarin Pharmaceutical and Vertex Pharmaceuticals also grant equity awards that vest upon achieving certain performance goals.
• The sale of shares to cover tax obligations is a common practice among executives in these companies, and the automatic sale mechanism is often used to ensure compliance with tax laws.

Stakeholder Impact

• The vesting of performance-based shares could be viewed positively by shareholders as it indicates the achievement of performance goals.
• The sale of shares by the CEO, even for tax purposes, could cause short-term fluctuations in the stock price, impacting shareholders.

Key Dates

Keywords

uniQure, Matthew Kapusta, performance-based restricted share units, PRSU, share acquisition, share sale, insider trading, executive compensation, tax obligations